NCT04033991View on ClinicalTrials.gov

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

CompletedOBSERVATIONAL
Enrollment

684

Participants

Timeline

Start Date

September 27, 2019

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
CarcinomaRenal Cell
Interventions
DRUG

Sunitinib

Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.

DRUG

Axitinib

Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.

Trial Locations (1)

Unknown

Pfizer UK, London

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04033991 - Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | Biotech Hunter | Biotech Hunter